Alpha-Defensin vs Exenatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Alpha-Defensin
Alpha-defensins are small cationic peptides that are key components of the innate immune system. They have broad-spectrum antimicrobial activity against bacteria, fungi, and some viruses.
Full details →Exenatide
Exenatide was the first GLP-1 receptor agonist approved in the US, derived from a compound found in Gila monster saliva. Available as Byetta (twice daily) and Bydureon (once weekly extended-release).
Full details →Side-by-Side Comparison
| Aspect | Alpha-Defensin | Exenatide |
|---|---|---|
| Mechanism | Insert into microbial membranes to form pores, leading to cell death. Also have immunomodulatory effects including chemotaxis of immune cells and cytokine modulation. | Synthetic version of exendin-4, which activates GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and promote satiety. |
| Typical Dosage | Research compound - dosing varies by application. Typically studied in laboratory and early clinical research settings rather than for general use. | Byetta: 5mcg twice daily for 1 month, then 10mcg twice daily. Bydureon: 2mg subcutaneously once weekly. |
| Administration | Various routes studied including topical, local injection, and systemic administration depending on application. | Byetta: Inject within 60 minutes before morning and evening meals. Bydureon: Any time of day, with or without meals. Do not mix with insulin in same syringe. |
| Side Effects | Limited human use data. May cause local inflammation. Potential for immune activation effects. | Nausea (especially initially), vomiting, diarrhea, dizziness, headache, and injection site reactions (particularly with Bydureon). |
| Best For |